Use of adoptive transfer and Winn assay procedures in the further analysis of antiviral acquired immunity in mice protected against Friend leukemia virus-induced disease by passive serum therapy

• Published in: Cancer research (Chicago, Ill.) Vol. 44; no. 4; pp. 1489 - 1498
• Main Authors: GENOVESI, E. V, PETTEY, C. L, COLLINS, J. J
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01-04-1984
• Subjects: Animal tumors. Experimental tumors; Animals; B-Lymphocytes - immunology; Biological and medical sciences; Experimental malignant blood diseases; Female; Friend murine leukemia virus - immunology; Immune Sera; Immunization, Passive; Leukemia, Experimental - immunology; Medical sciences; Mice; Mice, Inbred DBA; Spleen - immunology; T-Lymphocytes - immunology; Tumors; Viral Envelope Proteins - immunology; Immunoprotection; Oncovirinae; Acquired immunity; Rodentia; Retroviridae; Malignant hemopathy; B-Lymphocyte; Splenocyte; Infection; Virus; Vertebrata; Mammalia; Antiserum; Mouse; Type C oncovirus; Immunotherapy; Viral disease; T-Lymphocyte; Friend leukemia; Murine leukemia virus; Experimental tumor; Passive immunization; Macrophage
• ISSN: 0008-5472; 1538-7445

Previous studies have demonstrated that spleen cells from DBA/2 mice protected against challenge with a leukemogenic dose of Friend leukemia virus (FLV) by passive administration of xenogeneic antiviral or anti-FLV Mr 71,000 viral envelope glycoprotein antisera can adoptively transfer antiviral resistance to unimmunized irradiated syngeneic recipients. In addition, elimination of T-cells by treatment with anti-Thy 1.2 antibodies plus complement had no effect on the ability of spleen cells from serum-protected mice to adoptively transfer antiviral resistance. We now show that similar depletion of B-cells with rabbit anti-mouse immunoglobulin G plus complement or macrophages by adherence to Sephadex G-10 columns also leaves intact the protective capacity of spleen cells from serum-protected mice. That these results reflect the ability of more than one spleen cell population to transfer antiviral resistance rather than the activity of a non-T, non-B, nonmacrophage cell compartment is supported by the finding that purified splenic T- or B-cells alone from serum-protected DBA/2 mice can adoptively transfer antiviral resistance. Given the previously reported effects of sublethal irradiation on FLV leukemogenesis which could potentially complicate the interpretation of adoptive transfer experiments carried out in this system, analogous studies were performed using a Winn-type assay in which putative effector cells were preincubated with virus before inoculation of the mixture in unirradiated mice. These Winn assay experiments yielded identical results in that serum-protected spleen cells again prevented viral leukemogenesis, and the separate elimination of T-cells, B-cells, or macrophages had no effect on their protective activity. In addition, mixed transfer of serum-protected and normal spleen cells also protected irradiated mice against FLV challenge, providing further evidence that this adoptive protection truly reflects the presence of virus-specific effector cells in the spleens of serum-protected mice and not an inability of these spleen cells to replace radiation-sensitive viral target cells in recipient animals, since these should be supplied by the normal spleen cells in the transferred mixture.